Clesrovimab, formerly known as MK-1654, is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody.

"Clesrovimab administered as a single dose for infants of all weights provided protection against mild, moderate, and severe ...

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing ...

Merck has reported positive Phase IIb/III trial data for clesrovimab, its investigational RSV antibody, showing a 60.4% ...

In the study, clesrovimab (MK-1654) significantly reduced the incidence of RSV disease and hospitalisations in healthy ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

The drug clesrovimab also helped reduce RSV associated hospitalizations by 84.2% compared to placebo, Merck said.

Merck & Co., Inc. (MRK) announced the positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the ...

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval ...

Interim findings show clesrovimab has a similar safety profile to palivizumab. Clesrovimab, an investigational respiratory syncytial virus (RSV) fusion glycoprotein neutralizing monoclonal ...